1. OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s). (15th June 2017) Authors: Nash, P; Kirkham, B; Okada, M; Rahman, P; Combe, B; Adams, DH; Kerr, LN; Lee, CH; Shuler, CL; Genovese, MC Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0221 Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks. (15th June 2017) Authors: Heijde, D van der; Okada, M; Lee, C; Shuler, CL; Rathmann, S; Lin, C-Y; Mease, P Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗